Stem cell transplants may halt the progression of aggressive multiple sclerosis in nearly half of those with the debilitating disease, but picking the right patients for the treatment is key, a new study suggests. Specifically, younger patients with a relapsing form of MS who were not severely disabled and who hadn’t found relief with other treatments fared better than others over five years, the international team of researchers found.
Category: Lymphoma
Pluristem Therapeutics And New York Blood Center To Collaborate In…
Pluristem Therapeutics And New York Blood Center To Collaborate In Evaluating PLX-R18 As An Adjuvant Therapy To Umbilical Cord Blood Transplantation, Winning $900,000 Funding From BIRD Prior research has suggested that PLX-R18 helps cord blood cells to engraft more rapidly and effectively Grant of $900,000 from Israel-U.S. Binational Industrial Research and Development Foundation to fund the research Constitutes a 3rd potential hematologic indication for PLX-R18 HAIFA, Israel, Dec. 27, 2016 — Pluristem Therapeutics Inc. , a leading developer of placenta-based cell therapy products, today announced that it will collaborate with the New York Blood Center on preclinical studies of its Placental eXpanded -R18 cells to enhance the efficacy of umbilical cord blood transplantation.